2.12
+1.92%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Altimmune
From its filings with the US Securities and Exchange Commission
Altimmune is based in Morristown, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ALT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $41,000 and a net loss of $88.1m. At that date it held total assets of $279.9m and shareholders' equity of $224.9m.
We obtained pemvidutide as part of the acquisition Spitfire Pharma Inc., in July of 2019. Pemvidutide was designed as a MASH therapeutic based on the understanding that targeting both metabolic and liver-specific effects could lead to an improved and differentiated candidate. Early work provided compelling preclinical efficacy data obtained from a mouse model of MASH. Following a first-in-human clinical trial where we observed initial signs of weight loss and pronounced liver effects, we evaluated pemvidutide in participants with fatty liver disease, or metabolic-dysfunction associated liver disease (MASLD), where we observed robust reductions in liver fat content and weight loss. These results confirmed the earlier study and paved the way for the biopsy-driven IMPACT Phase 2b trial in MASH. To better characterize the quality of the weight loss and cardiometabolic effects of pemvidutide, the MOMENTUM Phase 2 trial in overweight and obese participants was conducted and showed significant weight loss characterized by relative sparing of lean muscle mass and improvements in serum lipids associated with cardiovascular disease. In addition to the recently completed IMPACT trial, pemvidutide is currently being evaluated in participants with AUD and, separately, ALD. There is evidence that pemvidutide may decrease the craving for alcohol in these individuals, with the added benefit that pemvidutide may reverse the harmful effects that alcohol has on the liver in these patients.
Quoted from its 10-K, filed 6 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Oct 2005
- Employees
- 57
- Website
- altimmune.com ↗
- Head office
- 910 CLOPPER ROAD, GAITHERSBURG, MD, 20878
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Mitchel SayareIndependent Director, since 2010$255,239
- Mr. Jerome DursoChairman of the Board, since 2025
- Dr. Vipin GargPresident, Chief Executive Officer, Director, since 2018$6.1m
- Mr. Gregory WeaverChief Financial Officer
- Dr. M. Scot RobertsChief Scientific Officer$2.4m
- Dr. Christophe Arbet-EngelsChief Medical Officer
- Dr. M. Scott HarrisChief Medical Officer$2.5m
- Mr. Raymond JordtChief Business Officer$2.9m
- Ms. Linda RichardsonChief Commercial Officer
- Mr. John GillIndependent Director, since 2007$239,239
- Mr. Philip HodgesIndependent Director$251,239
- Dr. Diane JorkaskyIndependent Director$231,239
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 45
- Social
- 38
- Governance
- 64
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Altimmune Inc has a strong intellectual property portfolio, which includes patents and proprietary technologies that provide significant competitive advantage in the pharmaceutical industry.
- The company's experienced management team and skilled workforce contribute to its expertise in vaccine development and immunotherapeutics.
- Altimmune Inc has established partnerships with leading organizations and institutions, fostering collaboration and enhancing its research and development capabilities.
Weaknesses
- Altimmune Inc relies heavily on a few key products, which increases its vulnerability to market fluctuations and regulatory challenges.
- The company's limited financial resources may hinder its ability to invest in research and development, marketing, and expansion into new markets.
- Altimmune Inc has a relatively small market share compared to some of its larger competitors, making it more difficult to penetrate established markets.
Opportunities
- The growing demand for vaccines and immunotherapeutics presents significant opportunities for Altimmune Inc to expand its product portfolio and increase market share.
- Advancements in technology and the increasing awareness of the importance of preventive healthcare create opportunities for the company to develop innovative solutions and gain a competitive edge.
- Altimmune Inc can explore strategic partnerships and collaborations to access additional resources, expertise, and new markets.
Threats
- The pharmaceutical industry is highly regulated, and changes in regulations and compliance requirements can pose challenges and increase costs for Altimmune Inc.
- Intense competition from larger pharmaceutical companies with established brands and resources poses a threat to Altimmune Inc's market share and growth.
- The ongoing COVID-19 pandemic has created a competitive landscape with increased focus on vaccine development, potentially increasing competition and reducing the market opportunities for Altimmune Inc.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.